@misc{oai:repo.qst.go.jp:00072359,
 author = {Hanyu, Masayuki and Fujinaga, Masayuki and Xie, Lin and Zhang, Yiding and Hatori, Akiko and Morokoshi, Yukie and Keiko, Li Huizi and Minegishi, Katsuyuki and Hasegawa, Sumitaka and Nagatsu, Kotaro and Zhang, Ming-Rong and 破入 正行 and 藤永 雅之 and 謝 琳 and 張 一鼎 and 羽鳥 晶子 and 諸越 幸恵 and 峯岸 克行 and 長谷川 純崇 and 永津 弘太郎 and 張 明栄},
 month = {May},
 note = {Metabotropic glutamate receptor 1 (mGluR1) is found ectopically in various kinds of cancers, such as melanoma and breast cancer. It has been reported that overexpressed mGluR1 exhibited oncogenic characteristics that independently trigger melanocyte tumorigenesis. Further, inhibition or inactivation of mGlu1 was demonstrated to prevent growth and progression of melanomas. Emipirical data indicate that mGlu1 is a promising molecular imaging target and could be applied for the diagnosis and personalized treatment of melanomas. Recently, we developed 4-[18F]fluoro-N-[4-(6-(isopropylamino)pyrimidin-4-yl)-1,3-thiazol-2-yl]-N-methylbenzamide ([18F]FITM) and its other halogen-substituted analogs as PET probes for in vivo imaging of mGluR1 in melanoma [1,2]. In this study, we radiosynthesized  4-[131I]iodo ([131I]1)- or 4-[211At]astato ([211At]1)- N-[4-(6-(isopropylamino)pyrimidin-4-yl)-1,3-thiazol-2-yl]-N-methylbenzamide as two target-radionuclide-therapy probes and  evaluated their antitumoral effects on mice bearing B16F10 melanoma. 
Unlabeled 1 and its tin precursor for the present radiosynthesis were prepared according to the method reported by our laboratory [2,3]. Radiosynthesis of [131I]1 was performed by reaction of tin precursor with [131I]NaI (280 MBq in 0.5 M NaOH) in the presence of 30% H2O2 at room temperature for 2 h. After purification and formulation, [131I]1 was obtained in 45 ± 20% radiochemical yield (n > 3, based on the total [131I]NaI). The molar radioactivity and radiochemical purity of [131I]1 were 40 ± 4 GBq/μmol and >99% at the end of synthesis. Treatment the B16F10-bearing mice with [131I]1 at 18 MBq and 9 MBq in 2 doses/mouse significantly reduced the tumor volumes (P < 0.05), compared to the untreated group, whereas treatment with [131I]NaI or unlabeled 1 did not show significant antitumoral effect (P > 0.05). PET with [18F]FITM further confirmed reduced uptake of radioactivity in the [131I]1-treated B16F10 tumor. 211At for radiolabeling was produced using a remotely controlled versatile system developed in house [4]. [211At]1 was successfully synthesized by the reaction of tin precursor with 211At in the presence of N-chlorosuccinimide at room temperature for 1 h. The radiochemical conversion of [211At]1 exceeded 40%. Optimized radiosynthesis and radiotherapy by [211At]1 for melanoma are in progress.
References: [1] L. Xie, et al. Int J Cancer, 2014, 135, 1852-59. [2] M. Fujinaga, et al. J Med Chem, 2015, 58, 1513-23. [3] M. Fujinaga, et al. J Med Chem, 2012, 55, 11042-51. [4] K. Nagatsu, et al. Appl Radiat Isot, 2014, 94, 363-71., 第10回アルファ線治療国際シンポジウムのポスター発表},
 title = {Synthesis and radiotherapeutic effect of two I-131 or At-211 labelled radioprobes for melanoma with overexpressed metabotropic glutamate receptor 1},
 year = {2017}
}